Oligomerix has received a $3.35m grant from the National Institutes of Health (NIH) unit National Institute on Aging to fund the clinical development of its lead candidate, OLX-07010, for Alzheimer’s disease (AD).
The company intends to commence a Phase Ia clinical trial of OLX-07010 in healthy subjects this year.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The randomised, double-blind, three-part trial will analyse the safety, tolerability and pharmacokinetics of single, multiple ascending doses as well as a single dose of OLX-07010 in healthy elderly subjects.
Such trials are anticipated to facilitate selecting the dosage of the therapy for further proof-of-concept studies in AD and other neurodegenerative diseases.
An oral tau self-association small molecule inhibitor, OLX-07010 acts on the beginning of the tau aggregation cascade.
This cascade is a process deemed to be vital for the development of AD, as well as various other neurodegenerative ailments.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn various animal models of tau-mediated neurodegeneration, the therapy showed efficacy.
Furthermore, the preclinical safety studies of OLX-07010 have concluded.
In June this year, the company raised $2.7m in an extension of its Series B financing round to further support preclinical and clinical development of its tau self-association inhibitor portfolio.
The funds will also be used for corporate reorganisation to move into clinical development and first-in-human testing.
Oligomerix CEO and head of discovery James Moe said: “Key requirements for treating early-stage AD include safe, efficacious, and cost-effective therapeutic interventions.
“Based on our preliminary results, this oral small molecule, CNS drug-like lead significantly fulfils these requirements.
“OLX-07010 is a highly differentiated tau self-association inhibitor targeting the beginning of the tau aggregation cascade.”
The company focuses on developing small molecule therapies that act on tau for rare neurodegenerative and Alzheimer’s diseases.
